Home Lexicon and Ipsen enter into ex-North America/Japan licensing and commercialization agreement for telotristat etiprate
 

Keywords :   


Lexicon and Ipsen enter into ex-North America/Japan licensing and commercialization agreement for telotristat etiprate

2014-10-22 15:11:12| Biotech - Topix.net

Ipsen and Lexicon Pharmaceuticals, Inc. today announced that they have entered into an exclusive licensing agreement for Ipsen to commercialize telotristat etiprate outside of North America and Japan, with a focus on the treatment of carcinoid syndrome. Lexicon retains sole rights to commercialize telotristat etiprate in the United States, Canada and Japan.

Tags: enter agreement licensing lexicon

Category:Biotechnology and Pharmaceuticals

Latest from this category

All news

»
24.111000 15
24.11 nike soccer usa national team uniform
24.1160266
24.11 1
24.11
24.11GREATEST HITS ALTER EGO EGOIST
24.11(ALINCO)
24.11[]34
More »